In case of a high prevalence of NTRK fusions in cancer types with a low incidence, such as the ETV6-NTRK3 fusions in secretory carcinomas, using a suboptimal pre-screening tool that requires confirmation is not practical. This evidence concerns the gene ETV6 and cancer.